Niagen Bioscience, Inc. Common Stock (NAGE)

• Market cap: $547M
• 1 day: 2.47%
• 5 days: -7.61%
• 1 month: 28.00%
• 3 months: 28.47%
• 6 months: 102.88%
• Year to date: 28.47%
• 1 year: 96.10%
• 5 years: 127.10%
• 10 years: 57.14%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

Employees: 104

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

644% more call options, than puts

Call options by funds: $1.53M | Put options by funds: $206K

486% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 7

81% more capital invested

Capital invested by funds: $65.5M [Q3] → $119M (+$53.3M) [Q4]

36% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 25

34% more funds holding

Funds holding: 91 [Q3] → 122 (+31) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $11 56% upside
• Avg. target: $11 56% upside
• High target: $11 56% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 50% 1-year accuracy 1 / 2 met price target

56% upside $11

Buy Reiterated

31 Mar 2025